
Sign up to save your podcasts
Or


Host: Perry Elliott
Guest: Hector Bueno
Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1796?resource=interview
Disclaimer:
ESC TV Today is supported by Bristol Myers Squibb.
This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor.
This programme is intended for health care professionals only and is to be used for educational purposes.
The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.
Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.
Declarations of interests:
Hector Bueno has declared to have potential conflicts of interest to report: research funding from the European Union (EU4H-2022-JA-03), Instituto de Salud Carlos III, Spain (FORTALECE program, PI21/01572), Sociedad Española de Cardiología, AstraZeneca, Boehringer Ingelheim, Janssen, and Novartis; and has received in the past consulting/speaking fees from Astra-Zeneca, Novartis, Novo Nordisk and Organon.
Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion.
By European Society of Cardiology5
55 ratings
Host: Perry Elliott
Guest: Hector Bueno
Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1796?resource=interview
Disclaimer:
ESC TV Today is supported by Bristol Myers Squibb.
This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor.
This programme is intended for health care professionals only and is to be used for educational purposes.
The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.
Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.
Declarations of interests:
Hector Bueno has declared to have potential conflicts of interest to report: research funding from the European Union (EU4H-2022-JA-03), Instituto de Salud Carlos III, Spain (FORTALECE program, PI21/01572), Sociedad Española de Cardiología, AstraZeneca, Boehringer Ingelheim, Janssen, and Novartis; and has received in the past consulting/speaking fees from Astra-Zeneca, Novartis, Novo Nordisk and Organon.
Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion.

140 Listeners

318 Listeners

499 Listeners

169 Listeners

884 Listeners

291 Listeners

3,349 Listeners

23 Listeners

140 Listeners

1,157 Listeners

512 Listeners

363 Listeners

17 Listeners

428 Listeners

3 Listeners